Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide

Muscle and Nerve

Volumn 47, Issue 2, 2013, Pages 292-296

  Leitch, Megan M ^a   Sherman, William H ^b   Brannagan, Thomas H ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Anti MAG antibodies neuropathy; CIDP; Cyclophosphamide; DADS; Fludarabine; Polyneuropathy

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; FLUDARABINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE;

AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DEMYELINATING NEUROPATHY; DISEASE COURSE; DISEASE SEVERITY; DISTAL ACQUIRED DEMYELINATING SYMMETRIC POLYNEUROPATHY; DRUG DOSE INCREASE; DYSPHAGIA; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; NERVE BIOPSY; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PARESTHESIA; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; QUADRIPLEGIA; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIBRATION SENSE;

CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVES; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME; VIDARABINE;

EID: 84873050587     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23629     Document Type: Article

References (23)

1. Barohn R, Kissel J, Warmolts J, Mendell J. Chronic inflammatory demyelinating polyradiculopathy. Annu Rev Med 1993; 44: 211-219.
2. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54: 615-619.
3. Dyck PJ, Dyck PJ. Atypical varieties of chronic inflammatory demyelinating neuropathies. Lancet 2000; 355: 1293-1294.
4. Brannagan TH. Immune-mediated chronic demyelinating polyneuropathies. In: Kalman B, Brannagan TH, editors. Neuroimmunology in clinical practice. Oxford: Blackwell; 2008. p 123-138.
5. Austin JH. Recurrent polyneuropathies and their corticosteroid treatment. Brain 1958; 81: 157-194.
6. Dyck PJ, O'Brien P, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-134.
7. Hahn JG, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077.
8. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055-1066.
9. Gorson KC, Allam G, Ropper AH. Chronic inflammatory mediated demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321-328.
10. Brannagan TH. Current treatments of chronic immune mediated demyelinating polyneuropathies. Muscle Nerve 2009; 39: 363-378.
11. Wilson HC, Lunn MPT, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fluadarbine. J Neurol Neurogurg Psychiatry 1999; 66: 575-580.
12. Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51: 1735-1738.
13. Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2005.
14. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
15. Ysebaert L, Gross E, Kuhlein E, Blanc A, Corre J, Fournie JJ, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010; 24: 1310-1316.
16. Latov N, Renaud S. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. J Neurol Sci 2004; 220: 127-129.
17. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy". Muscle Nerve 1995; 18: 440-444.
18. Shibuya K, Misawa S, Fukushima T, Uchiyama T, Funakoshi K, Kuwabara S. A case of chronic and progressive distal symmetric type CIDP with subacute exacerbation: focus on clinical pattern of CIDP. Rinsho Shinkeigaku 2011; 51: 141-144.
19. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32: 958-964.
20. Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999; 22: 560-566.
21. Viala K, Renie L, Maisonobe T, Behin A, Neil J, Leger JM, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004; 127: 2010-2017.
22. Gondim FA, de Sousa EA, Latov N, Sander HW, Chin RL, Brannagan TH. Anti-MAG/SGPG associated neuropathy does not commonly cause distal nerve temporal dispersion. J Neurol Neurosurg Psychiatry 2007; 78: 902-904.
23. Kaku DA, England JD, Sumner A. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994; 117: 941-947.